Finance Committee
- Referred To
Introduced: Mar 4, 2025
Latest action date: Mar 4, 2025
Latest development
Read twice and referred to the Committee on Finance.
Status detail: The most advanced recorded stage is committee consideration.
Plain-language overview
Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.
The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Civixly topics
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Health
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Sep 15, 2026.
Newest action first. Action language comes from the official Congress.gov record.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
0 comments
Loading comments...